Published in Gene Therapy Weekly, March 10th, 2005
This agreement enables Pharming to prepare for the market launch of rhC1INH for the treatment of hereditary angioedema, a life-threatening genetic disorder caused by a deficiency of the C1 inhibitor protein. Pharming has obtained an orphan drug designation from the U.S. Food and Drug Administration (FDA) and European Medicines Evaluation Agency for rhC1INH in treatment of hereditary as well as acquired form of angioedema.
Under the agreement, Akzo Nobel's Diosynth Biotechnology business is responsible...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.